title: Synergistic interactions between 12-0-tetradecanoylphorbol-13-acetate (TPA) and imatinib in patients with chronic myeloid leukemia in blastic phase that is resistant to standard-dose imatinib.
abstract: We have demonstrated that 12-0-tetradecanoylphorbol-13-acetate (TPA) combined with vitamin D(3) (VD(3)) and cytosine arabinoside (Ara C) is effective and feasible for chronic myelogenous leukemia (CML) in blastic phase (BP). In the current study, the efficacy of TPA combined with inhibitor imatinib mesylate (imatinib) was investigated in patients with CML in BP that was resistant to standard-dose imatinib (400mg/day). The results suggested that TPA combined with imatinib (400mg/day) might overcome disease-poor response to conventional doses. So this approach deserves further evaluation as frontline therapy for newly diagnosed CML.
authors: Henan Tumor Hospital, Henan Institute of Haematology, Henan Medical School, Henan University, 127 Dongming Road, Zhengzhou 450008, China.
authors: Baijun
authors: B
authors: Fang
authors: Yongping
authors: Y
authors: Song
authors: Zhengtao
authors: Z
authors: Han
authors: Xudong
authors: X
authors: Wei
authors: Quande
authors: Q
authors: Lin
authors: Xiaoxiu
authors: X
authors: Zhu
authors: Ruyu
authors: R
authors: Yang
authors: Junzhong
authors: J
authors: Sun
authors: Guofeng
authors: G
authors: Tian
authors: Xinjian
authors: X
authors: Liu
authors: Guoshun
authors: G
authors: Cao
authors: Yin
authors: Y
authors: Shi
authors: Neng
authors: N
authors: Nie
authors: Dapeng
authors: D
authors: Li
authors: Robert Chunhua
authors: RC
authors: Zhao
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001549:Benzamides; D001752:Blast Crisis / Q000188:drug therapy*; D019008:Drug Resistance, Neoplasm; D004357:Drug Synergism; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage; D011743:Pyrimidines / Q000008:administration & dosage; D013755:Tetradecanoylphorbol Acetate / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D013755:Tetradecanoylphorbol Acetate